Q4 Earnings Forecast for VIGL Issued By William Blair

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Research analysts at William Blair issued their Q4 2024 earnings estimates for Vigil Neuroscience in a research report issued on Wednesday, January 8th. William Blair analyst S. Schram forecasts that the company will post earnings of ($0.20) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience’s Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.59) EPS and Q4 2025 earnings at ($0.64) EPS.

A number of other equities research analysts have also commented on VIGL. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, Wedbush increased their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $19.75.

Vigil Neuroscience Stock Performance

Shares of VIGL opened at $1.79 on Monday. The stock has a 50-day moving average of $2.40 and a two-hundred day moving average of $3.24. The stock has a market cap of $73.17 million, a P/E ratio of -0.87 and a beta of 1.76. Vigil Neuroscience has a one year low of $1.49 and a one year high of $6.06.

Institutional Trading of Vigil Neuroscience

A number of hedge funds have recently added to or reduced their stakes in VIGL. Ensign Peak Advisors Inc raised its position in shares of Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after acquiring an additional 166,442 shares during the period. abrdn plc purchased a new position in shares of Vigil Neuroscience in the 3rd quarter valued at about $799,000. Point72 Asset Management L.P. acquired a new position in Vigil Neuroscience in the 2nd quarter worth about $5,940,000. Geode Capital Management LLC boosted its position in Vigil Neuroscience by 41.9% during the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after purchasing an additional 66,712 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in Vigil Neuroscience in the third quarter valued at approximately $442,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.